In Vitro Models of Liver and Pancreatic Cancer

A Study Designed to Develop in Vitro Models of Liver, Biliary and Pancreatic Cancer for the Investigation of Tumour Biology and Potential Therapies

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02436564

Enrollment

Registered

2015-05-07

Start date

2015-07-31

Completion date

Unknown

Last updated

2016-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholangiocarcinoma, Hepatocellular Carcinoma, Pancreatic Neoplasm

Keywords

pancreas, stem cells, tumours, in vitro models, organoids, cancer,, bile duct, liver

Brief summary

The primary objective is to develop an in vitro model of cancer for laboratory study using liver, biliary and pancreatic cancer tissue. The secondary objective is to study the genetic and cellular biology of cancer of the liver, biliary tract and the pancreas. As well the investigators hope to compare molecular and cellular biology of cancer cells with normal cells as well as potentially test the efficacy of current and future anti-cancer therapies. Samples will be collected from tissue that has been resected as part of the treatment for a patient diagnosed with liver, bile duct or pancreas cancer.

Interventions

GENETICOrganoid in vitro culture

Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* All adult patients undergoing surgical resections for liver, biliary or pancreas cancers that are able to give informed consent.

Exclusion criteria

* Patients aged \<18 or those who are unable to give informed consent.

Design outcomes

Primary

Measure	Time frame
Number of tumour-derived organoids successfully cultured in vitro for a minimum of 3 months.	3 years

Secondary

Measure	Time frame
Proportion of tumour-derived organoids that are genetically identical to the source tumour.	3 years

Countries

United Kingdom

Contacts

Primary ContactKourosh Saeb-Parsy, PhD, FRCS

ks10014@cam.ac.uk(+44 1223 7) 68456

Backup ContactNikitas Georgakopoulos, BSc

ng395@cam.ac.uk07554003700

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026